Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + rapamycin
- Development stage
- Phase 2
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intravenous, Oral
01
Overview
A combination therapy consisting of gemcitabine, a nucleoside analog that acts as an antimetabolite, and rapamycin (sirolimus), an mTOR inhibitor. This combination demonstrates synergistic effects in cancer treatment, particularly for pancreatic cancer and certain sarcomas. Gemcitabine inhibits DNA synthesis and causes cell cycle arrest at the S phase, while rapamycin inhibits the mTOR pathway, affecting cell growth, proliferation, and survival. Studies show that gemcitabine induces mTOR pathway hyperactivation, which rapamycin effectively counteracts, leading to enhanced anticancer effects.
- Other names
- gemcitabine + sirolimus
02
Targets
Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on gemcitabine + rapamycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + rapamycin.